Physician Education: Bridging Clinical Research and Patient Care

TAM Posttest

Continuing Medical Education Posttest

The following Topics in Antiviral Medicine™ issue offers continuing medical education (CME) credit:

May/June 2016, Volume 24, Issue 1

Overview

  • CME Credit Available: 15.0 AMA PRA Category 1 Credits
  • Release Date: June 7, 2016
  • Expiration Date: June 7, 2017

To complete the activity, read each article and successfully complete the posttest and evaluation form, which will help us evaluate this activity and plan future activities. Your responses will not affect your CME credit.

Learning Objectives

On completion of this activity, participants will be able to describe the important new data presented at the 2016 Conference on Retroviruses and Opportunistic Infections and the potential clinical implications for patients in the areas of:

  • Pathogenesis of HIV disease
  • Epidemiology of HIV and HIV prevention efforts
  • Neurologic disorders in HIV disease and their treatment
  • Complications of HIV disease and HIV-related coinfection
  • Viral hepatitis
  • Antiretroviral therapy

Assessment of Needs

The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians on the evolving challenges of managing HIV disease. This activity examines new data presented at the 2016 Conference on Retroviruses and Opportunistic Infections and the potential clinical implications for patients.

Intended Audience

This enduring material is designed for physicians and other health care practitioners who are actively involved in the medical care of people with HIV infection.

This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.

CME Information

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The IAS–USA designates this enduring material for a maximum of 15.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME activity is offered from June 7, 2016, to June 7, 2017. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Other health care practitioners will receive a certificate of participation.

Disclosure of Financial Interests

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, authors, IAS–USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing medical education activity is delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

Dr Buchbinder has participated in research trials that have received provision of medicines from Gilead Sciences, Inc. (Updated 04/28/16)

Dr Liu has participated in research trials that have received provision of medicines from Gilead Sciences, Inc. (Updated 04/09/16)

Dr Luetkemeyer has received grants awarded to her institution from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, and Merck & Co, Inc, and has received travel support from Bristol-Myers Squibb and Gilead Sciences, Inc. (Updated 04/19/16)

Dr Wilkin has received research grants paid to his institution from Bristol-Myers Squibb and Gilead Sciences, Inc. Dr Wilkin’s spouse was an employee of and has stock options from Johnson & Johnson. (Updated 06/02/16)

Dr Wyles has received research grants awarded to his institution from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, and Tacere Therapeutics, Inc. He has also served as a consultant for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, and Merck & Co, Inc. (Updated 04/26/16)

Dr Tieu has received research grants paid to her institution from Merck & Co, Inc. (Updated 06/02/16)

Dr Richman has been a consultant to Antiva Biosciences, Chimerix, Gilead Sciences, Inc, and Monogram Biosciences, Inc. (Updated 06/15/16)

Dr Benson serves on a data and safety monitoring board for GlaxoSmithKline/ViiV Healthcare. She has received research grants awarded to the University of California San Diego from AbbVie, Gilead Sciences, Inc, and ViiV Healthcare. Her spouse, Robert T. Schooley, MD, has served as a scientific advisor for CytoDyn and Gilead Sciences, Inc, and was awarded research grants, paid to his institution, from Boehringer Ingelheim Pharmaceuticals, Inc, and Bristol-Myers Squibb. His institution has received payment for his consultative advice and/or data monitoring committee service from GlobeImmune, Gilead Sciences, Inc, and Monogram Biosciences. He serves as a consultant to CytoDyn, Hera Therapeutics, and Farmak. He has stock options from CytoDyn, Hera Therapeutics, and GlobeImmune. (Updated 04/25/16)

Dr Ances has no relevant financial affiliations to disclose. (Updated 04/26/16)

Dr Currier has no relevant financial affiliations to disclose. (Updated 05/12/16)

Dr Havlir has no relevant financial affiliations to disclose. (Updated 05/12/16)

Dr Hirsch has no relevant financial affiliations to disclose. (Updated 06/15/16)

Dr Olender has no relevant financial affiliations to disclose. (Updated 06/02/16)

Dr Spudich has no relevant financial affiliations to disclose. (Updated 04/26/16)

Dr Stevenson has relevant financial affiliations to disclose. (Updated 05/10/16)

Dr Taylor has no relevant financial affiliations to disclose. (Updated 06/02/16)

Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 06/07/16)

The nonstaff members of the Topics in Antiviral Medicine™ Editorial Board participate in a volunteer capacity. They are not compensated for their role in overseeing the program.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors:

Independent educational grants for the 2016 Improving the Management of HIV Disease® CME program:

PLATINUM SUPPORTER
ViiV Healthcare

SILVER SUPPORTERS
Bristol-Myers Squibb
Gilead Sciences, Inc
Janssen Therapeutics
Merck & Co, Inc

Drug and Product Disclaimer

This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.

The views and opinions expressed herein are those of faculty and do not necessarily represent the opinions or recommendations of IAS–USA.

Contact Information

If you have any questions about this activity, please contact the IAS–USA:

E-mail: journal“at”iasusa.org
Mail: 425 California Street, Suite 1450, San Francisco, CA 94104-2120
Phone: 415-544-9400
Fax: 415-544-9401

By clicking “Begin,” I acknowledge that I have read these instructions and understand them.

You must log in to take the activity.

Begin